Biotech
SeaStar Medical Expands Acute Kidney Injury Treatment Strategy with Promising Q1 Performance
SeaStar Medical reports significant growth in pediatric acute kidney injury treatment QUELIMMUNE and advances plans to enter the larger adult market, with potential to address a $4.5 billion annual opportunity.
Aditxt Terminates Acquisition Agreement with Appili Therapeutics
Aditxt Inc. has decided to end its planned acquisition of Appili Therapeutics, citing a lack of strategic alignment. The termination highlights potential challenges in healthcare innovation partnerships.
Tonix Pharmaceuticals Advances Fibromyalgia Drug, Reports Q1 Financial Results
Tonix Pharmaceuticals is poised for potential FDA approval of TNX-102 SL, a novel non-opioid fibromyalgia treatment, while maintaining a robust research pipeline and strong cash position. The drug could represent a significant breakthrough in fibromyalgia treatment after more than 15 years without a new drug class.
TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
TransCode Therapeutics will execute a reverse stock split to increase its per-share price and meet Nasdaq listing requirements, reducing outstanding shares from 23.3 million to approximately 833,620.
NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.
NeuroSense Advances Promising ALS Treatment with Potential Global Partnership
Biotech company NeuroSense Therapeutics is in advanced discussions for a pharmaceutical partnership that could accelerate its innovative ALS treatment PrimeC, demonstrating significant survival improvements in clinical trials.
NeuroSense's ALS Drug PrimeC Shows Promise with 58% Survival Improvement, Pharmaceutical Partnership Imminent
NeuroSense Therapeutics' experimental ALS treatment PrimeC demonstrates significant potential in clinical trials, with the company positioned for a major pharmaceutical partnership and potential breakthrough in neurodegenerative disease treatment.
Quantum BioPharma Announces Corporate Updates and Debt Settlement Strategy
Quantum BioPharma Ltd. has granted restricted share units and approved debt settlement through share issuance, signaling strategic financial maneuvering and potential investment opportunities in the biotech sector.